← All MEPs

Daniel Caspary

European Parliament · 🇩🇪 Germany · former MEP

Term: from 18 July 2019 to 24 February 2026

Participation in roll-call votes

91 % of the 2,244 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 21 % (4 / 19), presence 21 % (4 / 19) November 2019 : participation 94 % (17 / 18), presence 94 % (17 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 100 % (8 / 8), presence 100 % (8 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 100 % (19 / 19), presence 100 % (19 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 100 % (31 / 31), presence 100 % (31 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 96 % (26 / 27), presence 96 % (26 / 27) December 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 97 % (36 / 37), presence 97 % (36 / 37) April 2022 : participation 91 % (20 / 22), presence 91 % (20 / 22) May 2022 : participation 85 % (75 / 88), presence 85 % (75 / 88) June 2022 : participation 91 % (42 / 46), presence 91 % (42 / 46) July 2022 : participation 68 % (21 / 31), presence 68 % (21 / 31) September 2022 : participation 96 % (24 / 25), presence 96 % (24 / 25) October 2022 : participation 91 % (29 / 32), presence 91 % (29 / 32) November 2022 : participation 24 % (9 / 38), presence 24 % (9 / 38) December 2022 : participation 89 % (16 / 18), presence 89 % (16 / 18) January 2023 : participation 81 % (13 / 16), presence 81 % (13 / 16) 2023 February 2023 : participation 97 % (28 / 29), presence 97 % (28 / 29) March 2023 : participation 55 % (16 / 29), presence 55 % (16 / 29) April 2023 : participation 100 % (24 / 24), presence 100 % (24 / 24) May 2023 : participation 97 % (90 / 93), presence 97 % (90 / 93) June 2023 : participation 90 % (36 / 40), presence 90 % (36 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 96 % (26 / 27), presence 96 % (26 / 27) October 2023 : participation 95 % (38 / 40), presence 95 % (38 / 40) November 2023 : participation 100 % (53 / 53), presence 100 % (53 / 53) December 2023 : participation 95 % (38 / 40), presence 95 % (38 / 40) January 2024 : participation 96 % (47 / 49), presence 96 % (47 / 49) 2024 February 2024 : participation 75 % (47 / 63), presence 75 % (47 / 63) March 2024 : participation 84 % (42 / 50), presence 84 % (42 / 50) April 2024 : participation 89 % (190 / 213), presence 89 % (190 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 100 % (8 / 8), presence 100 % (8 / 8) October 2024 : participation 92 % (12 / 13), presence 92 % (12 / 13) November 2024 : participation 100 % (27 / 27), presence 100 % (27 / 27) December 2024 : participation 61 % (11 / 18), presence 61 % (11 / 18) January 2025 : participation 100 % (6 / 6), presence 100 % (6 / 6) 2025 February 2025 : participation 100 % (10 / 10), presence 100 % (10 / 10) March 2025 : participation 79 % (11 / 14), presence 79 % (11 / 14) April 2025 : participation 100 % (22 / 22), presence 100 % (22 / 22) May 2025 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2025 : participation 91 % (20 / 22), presence 91 % (20 / 22) July 2025 : participation 81 % (26 / 32), presence 81 % (26 / 32) September 2025 : participation 100 % (29 / 29), presence 100 % (29 / 29) October 2025 : participation 98 % (44 / 45), presence 98 % (44 / 45) November 2025 : participation 71 % (36 / 51), presence 71 % (36 / 51) December 2025 : participation 97 % (30 / 31), presence 97 % (30 / 31) January 2026 : participation 91 % (20 / 22), presence 91 % (20 / 22) 2026 February 2026 : participation 68 % (19 / 28), presence 68 % (19 / 28)

Their votes

2,244 votes

DateTextResultTheir vote
Exceptional trade measures for countries and territories participating in or linked to the Stabilisation and Association process (codification) ✓ Adopted For
Competition policy – annual report 2023 ✓ Adopted Absent
Implementation of the Erasmus+ programme 2021-2027 ✓ Adopted For
Current and future challenges regarding cross-border cooperation with neighbouring countries ✓ Adopted For
Electric aviation – a solution for short- and mid-range flights ✓ Adopted For
Banking Union – annual report 2023 ✓ Adopted For
Ozone depleting substances ✓ Adopted For
Fluorinated gases regulation ✓ Adopted For
The abduction of Tibetan children and forced assimilation practices through Chinese boarding schools in Tibet For
Attempt of coup d’Etat in Guatemala For
The unknown status of Mikalai Statkevich and the recent attacks on Belarusian politicians’ and activists’ family members For
The Maasai Communities in Tanzania For
Frontex, building on the fact-finding investigation of the LIBE Working Group for Frontex Scrutiny Absent
Objection pursuant to Rule 112(2) and (3): Genetically modified maize Bt11 × MIR162 × MIR604 × MON 89034 × 5307 × GA21 and thirty sub-combinations Against
Objection pursuant to Rule 112(2) and (3), and (4)(c): Maximum residue levels for tricyclazole For
Objection pursuant to Rule 112(2) and (3): Genetically modified oilseed rape Ms8, Rf3 and Ms8 × Rf3 Against
Objection pursuant to Rule 112(2) and (3), and (4)(c): Maximum residue levels for fipronil Against
European Hydrogen Bank For
Jurisdiction, applicable law, recognition of decisions and acceptance of authentic instruments in matters of parenthood and creation of a European Certificate of Parenthood Absent
Increasing innovation, industrial and technological competitiveness For
30 years of Copenhagen criteria - giving further impetus to EU enlargement policy For
Adjustments of the size criteria for micro, small, medium-sized and large undertakings or groups For
EU-China relations For
Non-communicable diseases For
The situation of children deprived of liberty in the world For
The role of EU development policy in transforming extractive industries for sustainable development in developing countries Against
European Health Data Space For
EU-US relations For
Implementation of the 2018 Geoblocking Regulation in the Digital Single Market For
EU-Japan relations For
EU development cooperation to enhance access to education and training in developing countries For
Implementation of the Treaty provisions on special legislative procedures For
Foodstuffs for human consumption: amending certain 'Breakfast' Directives For
Minimum requirements on minimum breaks and daily and weekly rest periods in the occasional passenger transport sector For
EC/Kiribati Fisheries Partnership Agreement (2023-2028). Implementation Protocol For
Mental health For
Addictive design of online services and consumer protection in the EU single market For
Small modular reactors For
Further reform of corporate taxation rules For
Fees and charges payable to the European Medicines Agency For

Rows per page: 20 40 100 200 All